ENDOLOWis an Investigator-Initiated Study (IIS) funded by J&J/Cerenovus and sponsored by Emory University. The trial is a Phase 2/3 designed trial testing immediate endovascular mechanical thrombectomy vs. initial medical management for large vessel occlusions in patients with NIHSS 0-5.
This is a $5.8 million award to Drs. Raul Nogueira and David Wright.
Emory Emergency Neurosciences is providing study wide management across 50 sites in the US, Canada, and Europe. We have partnered with Investigators at the University of Cincinnati, University of Calgary, and the University of Heidelberg. Enrollment at Grady is expected to start in late summer of 2019.
ENRICH
The ENRICH (Early MiNimally-invasive Removal of IntraCerebral Hemorrhage) clinical trail compared standard medical management to early ICH evacuation using minimally invasive parafascicular surgery for the treatment of acute spontaneous supratentorial ICH.
With the results of the 6-year ENRICH clincial trial, the investigators have concluded that "minimally invasive parafascicular surgery (MIPS) offers significant improvements in outcomes for patients ICH. MIPS not only led to a statistically significant enhancement in utility-weighted modified Rankin Scale (UWmRS) scores at 180 days, but also reduced mortality rates at 30 days and shortened both ICU and hospital stays." (Emory News Center)
At Emory, the ENRICH research team was comprised of a cross-disciplinary team from neurosciences and emergency medicine. Emory University faculty members on this research include: co-principal investigator Dan Barrow, MD, co-lead investigator Gustavo Pradilla, MD, co-principal investigator Jonathan Ratcliff, MD (Emory Emergency Medicine); Michael Frankel, MD; Jason W. Allen, MD, PhD; David Wright, MD (Emory Emergency Medicine); and Alex Hall, DHSc, MS, RN (Emory Emergency Medicine).
Learn more about the Emory-led ENRICH trial in this Emory News Center article. The study was published in the New England Journal of Medicine and can be found here.
In the photograph to the right, Emory EM's Alex Hall, DHSc, MS, RN, is presenting on ENRICH to the European Stroke Organization Congress in Munich, Germany.
REACH
Building on the ENRICH study, the Rapid Evacuation and Access of Cerebral Hemorrhage (REACH) trial and its companion REACH registry are led by the Emory University School of Medicine and the Grady Health System’s Marcus Stroke and Neuroscience Center. The REACH trial is a multicenter clinical trial that will continue through 2028 and is being funded by The Marcus Foundation. It is the first study to investigate the use of minimally invasive parafascicular sugery (MIPS) for deepintracerebral hemorrhage (ICH), particularly within the anterior basal ganglia.
"The REACH trial will explore treatment for intracerebral hemorrhage (ICH), a severe form of hemorrhagic stroke where bleeding from a ruptured vessel occurs directly within the brain tissue, causing severe damage to brain cells and disrupting vital brain functions." (Emory News Center)
"In addition to optimizing the MIPS technique and demonstrating its safety and efficacy, REACH will establish new guidelines for treating patients with ICH in the brain’s basal ganglia. The accompanying REACH registry will build a comprehensive data repository, guiding future clinical practices and promoting broader adoption of MIPS for patients with spontaneous ICH." (Emory News Center)
The REACH trial principal investigators include: Gustavo Pradilla, MD, Neurosurgery, Jonathan Ratcliff, MD, MPH, Emory Emergency Medicine, and Alex Hall, DHSc, MS, Emory Emergency Medicine. Read more about REACH in this Emory News Center article.
VICTASÂ
VICTAS is a trial to see if the use of vitamin C, thiamine, and corticosteroids reduces the duration of respiratory and cardiovascular organ dysfunctionin critically ill patients with sepsis. The trial is sponsored by Emory University and funded by a grant from The Marcus Foundation.
TEaM
Emory and CHOA Investigators are partnering on an exciting new research project, TBI Evaluation and Management (TEaM), funded by the Centers for Disease Control and Prevention that focuses on mild traumatic brain injury (concussions) in children ages 5 – 18. The goal of TEaM is to improve both the detection of pediatric concussion and accurate diagnosis as well as communication between providers (ED, UC, and PCP), concussed children and their families, and schools.
